Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERICLES phase 2 atezolizumab study in advanced penile cancer
NL-OMON52808Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in penile cancer and urethral cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival at 1 year. Started Oct 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
penile cancerurethral cancer
Beyond the preview
Go deeper on NL-OMON52808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52808.